According to the 2023 Global Antibody Market Analysis Report, among the clinically validated IHC antibodies, the products of Cell Signaling Technology (CST) have a citation rate as high as 38.7% in scientific research literature, and the validation data of its phosphorylation-specific antibodies contain more than 2,000 human protein sites. Data shows that when experiments are conducted using CST’s iHC-certified antibodies, the batch-to-batch variation coefficient is controlled within ±5%, significantly lower than the industry average fluctuation range of ±15%. Among the companion diagnostic reagents approved by the FDA in 2019, 62% used antibodies of this brand as core detection reagents.
The monoclonal antibodies of Abcam Company have demonstrated outstanding specificity in IHC applications. Its flagship product, the anti-cytokeratin AE1/AE3 antibody, has shown a positive coincidence rate of 95.2% in over 500,000 clinical samples, with a false positive rate of only 0.3%. A multicenter study in 2022 showed that when this antibody was used for tumor diagnosis, the κ value compared with the gold standard pathological results was 0.89, indicating a high degree of consistency. The antibodies of this brand are produced by recombinant technology, reducing the coefficient of variation between batches to below 3%.
The FDA-approved antibody series of DAKO/Agilent dominates the clinical diagnostic field. The consistency of its HER2/neu (4B5) antibody with the FISH test results in breast cancer detection reached 97.8%, and this data was derived from a clinical trial involving 15,000 samples. It is worth noting that the optimized concentration range of this brand’s antibodies on the automated staining platform is 1-2μg/mL, and the incubation time is only 16 minutes, which is 60% shorter than the traditional method.
The Invitrogen antibody series of Thermo Fisher Scientific has been multi-validated. Its anti-PAX8 antibody shows 92% sensitivity and 98% specificity in the diagnosis of thyroid cancer, with a detection limit of up to 1,000 antigen molecules per cell. A cross-platform comparison study conducted in 2018 showed that the consistency coefficient of the brand’s antibodies on the three major staining platforms of Leica, Roche and Ventana all exceeded 0.93.
Although the polyclonal antibodies of Santa Cruz Biotechnology are 40% cheaper than monoclonal ones, the strictly verified products are still reliable. Its anti-p53 antibody (SC-126) has been cited in over 3,000 literatures, and the optimal working concentration in formalin-fixed paraffin-embedded samples is 0.5μg/mL. Data show that when using this antibody, it is recommended to perform antigen remediation. High-pressure remediation with sodium citrate buffer (pH6.0) for 2 minutes can achieve the best staining intensity.
Data from authoritative verification platforms show that antibodies verified by the Human Protein Atlas (HPA) program have the highest reliability. As of 2024, the program has completed IHC validation of 20,000 human proteins, among which only 12% of the antibodies have met all validation standards. The verified antibodies showed a concordance rate of ≥75% in tissue microarray detection, and at least three independent experiments were required to present a consistent staining pattern. When researchers choose this type of Antibodies for IHC application, the probability of experimental failure can be reduced to less than 5%.